Top Biotech Movers (CTIC, CXM, ITMN, GNOM, GEVA)

Cell Therapeutics, Inc. (NASDAQ: CTIC) declined 3.57% to $1.08 in the morning hours after the company announced that on February 9, 2012 the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI’s resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who failed two or more lines of prior therapy.

Cardium Therapeutics Inc (NYSEAMEX: CXM) soared 22.52% to $0.370 in the early hour after the company announced that it has entered into its first international agreement for the commercialization of Excellagen in the South Korean market.

InterMune, Inc. (NASDAQ: ITMN) gained 3.95% to $13.65 after the company announced unaudited net sales of Esbriet (pirfenidone) for the fourth quarter ended December 31, 2011, as well as information on the number of patients that initiated Esbriet therapy in Germany during 2011.

Complete Genomics, Inc. (NASDAQ: GNOM) fell 0.85% to $3.48 in the early hour. The 52 week trading range for the company is $2.57 – $18.55. The company has declined over 57% in the last one year. Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform.

Synageva BioPharma Corp. (NASDAQ: GEVA) climbed 8.42% to $27.30 in the early hour after the company announced the pricing of its previously announced underwritten public offering of common stock consisting of 3,108,057 shares at $25.18 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 466,209 additional shares of common stock to cover over-allotments, if any.


The assembled information distributed by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented herein. will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.

Tagged with: | | | |
Our Research Report on CTIC is now available. Don´t Trade CTIC until you Read our FREE FULL REPORT. Click Here